Physician profile

Thomas K Pow

Interventional Cardiology · Saint Joseph, MI

NPI 1174583199

$11,148.58

in general payments reported to CMS, 2019-2025

40 companies · $1,812 in 2025

The $1,812 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,288.40

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $2,981.65 2021-2025 Corevalve Evolut R, Telescope
Penumbra, INC. $1,060.32 2019
Novartis Pharmaceuticals Corporation $706.18 2019-2025
Abbott Laboratories $681.34 2019-2025 Optis, Coroflow, Diamondback Peripheral
Edwards Lifesciences Corporation $570.36 2019-2025 Sapien 3 Ultra Resilia, Inspiris Resilia Aortic Valve
Boston Scientific Corporation $519.42 2020-2025 Ranger, Innova Vascular, General - Metallic Stents
Cook Medical LLC $414.17 2019-2020
Janssen Pharmaceuticals, INC $411.48 2019-2023 Xarelto
E.R. Squibb & Sons, L.L.C. $371.14 2019-2025 Eliquis, Camzyos
Amgen INC. $359.72 2020-2022
Shockwave Medical, INC $341.87 2022-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Boehringer Ingelheim Pharmaceuticals, INC. $334.15 2019-2025 Jardiance
Medtronic Vascular, INC. $267.72 2019-2020
Pfizer INC. $251.68 2019-2025
Philips North America LLC $198.86 2022-2024 (Az7) Lasers
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $161.50 2019-2024 Wainua, Brilinta, Farxiga
Esperion Therapeutics, INC. $152.74 2020-2023 Nexletol
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $151.67 2019-2025 Lifevest
Teleflex LLC $123.88 2019
Lantheus Medical Imaging, INC. $119.46 2021
Chiesi USA, INC. $106.08 2021
Terumo Medical Corporation $93.84 2024 Azur Cx Detachable
Angiodynamics, INC. $82.47 2022-2023 Venacure 1470 Pro
Bayer Healthcare Pharmaceuticals INC. $80.33 2021-2025
Abiomed $74.69 2025
Inspire Medical Systems, INC. $71.22 2025 Inspire
Amarin Pharma, INC. $71.18 2019-2022
Biosense Webster, INC. $62.53 2022
Endologix LLC $55.81 2019
Lundbeck LLC $51.77 2019
Alexion Pharmaceuticals, INC. $38.27 2021-2022
Sanofi-Aventis U.S. LLC $34.06 2019-2023
Gilead Sciences, INC. $30.99 2019-2023
W. L. Gore & Associates, INC. $21.38 2024 Gore Excluder Aaa Endoprosthesis
Alnylam Pharmaceuticals INC. $20.29 2022
Daiichi Sankyo INC. $20.21 2024 Injectafer
Scpharmaceuticals INC. $19.89 2024
Cardiva Medical, INC. $17.66 2021
Actelion Pharmaceuticals US, INC. $12.34 2021
Cardiovascular Systems INC. $4.26 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas K Pow

$11,148.58

in general payments reported 2019-2025

Years
2019-2025
Top company
Medtronic, INC.
Context
The $1,812 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/280636/thomas-k-pow

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.